Jenny M H Chen

3PUBLICATIONS
6CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Mar 18, 2024
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.

Gilles Salles, Jenny M H Chen, Ina Zhang

|Oct 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.

Georg Hess, Martin Dreyling, Lucie Oberic

|Oct 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.

Georg Hess, Martin Dreyling, Lucie Oberic

Pageof 1

Frequent Collaborators

2 joint publications

Sam Keeping

1 joint publications

Georg Hess

1 joint publications

Lucie Oberic

1 joint publications

Pier Luigi Zinzani